TH-302,Hypoxia-activatedPro-drug M60089-5s|产品详情|进口橙子视频旧款采购网

您好，欢迎来到橙子视频app安卓下载生物网站！请登录注册

我的订单 | 联系橙子视频app安卓下载 | 在线客服QQ：3012681483 | 客服电话：400-968-7988 | 工作时间：08:30-17:30

主营产品： ELISA91橙子视频、抗体、补体血清、兔补体、干扰素、小鼠测温仪、进口橙子视频旧款、Quidel代理、Swant代理、PBL Assay Science代理

网站首页产品中心代理品牌新闻资讯资源中心关于橙子视频app安卓下载

所在位置：首页 > 产品中心 > Xcessbio > Xcessbio产品

订购信息

上海橙子视频app安卓下载生物科技公司

Tel:400-968-7988 021-33779008

TH-302,Hypoxia-activatedPro-drug

品牌：Xcessbio

货号：M60089-5s

规格：5 mg solid

货期：

应用：

咨询客服

立即购买加入购物车

TH-302,Hypoxia-activatedPro-drug

商品详情参考文献相关资料

Product Information

Molecular Weight:	449.04
Formula:	C₉H₁₆FBr₂N₆O₄P
Purity:	≥ 98%
CAS#:	918633-87-1
Solubility:	DMSO up to 50 mM
Chemical Name:	(1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis(2-bromoethyl)phosphordiamidate
Storage:	Powder: 4^oC 1 year. DMSO: 4^oC 3 month; -20^oC 1 year.

Biological Activity:

TH-302 is a highly potent and selective hypoxia-activated pro-drug targeting hypoxic regions of solid tumors with an IC₅₀ of 19 nM. It is stable to liver microsomes. However, under hypoxic conditions, it is selectively and irreversibly converted to its active phosphoramidate-based, DNA-crosslinking, bis-alkylator. TH-302 inhibits H460 cells and HT29 cells with IC₉₀ of 0.1 μM and 0.2 μM, respectively. It shows much enhanced potency in H460 spheroids compared to H460 monolayer cells under normoxia. TH-302 exhibits potent cytotoxicity to both human and murine MM cells with hypoxic selectivity and dose dependency, and induces G0/G1 cell-cycle arrest under hypoxic conditions. It inhibits primary tumor growth in multiple xenograft models. TH-302 is currently in a phase II clinical trial for the treatment of soft tissue sarcoma.

How to Use:

In vitro: TH-302 was used at 1 µM concentration in vitro and cellular assays.
In vivo: TH-302 was intraperitoneally (IP) dosed to mice at 50 mg/kg once per day to inhibit tumor growth.

Reference:

1. Duan JX, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. (2008) J Med Chem. 51(8):2412-20.
2. Hu J, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. (2010) Blood. 116(9):1524-7.
3. Weiss GJ, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. (2011) Clin Cancer Res. 17(9):2997-3004.
4. Meng F, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. (2012) Mol Cancer Ther. 11(3):740-51.
5. Sun JD, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. (2012) Clin Cancer Res. 18(3):758-70.
6. Moyer MW. Targeting hypoxia brings breath of fresh air to cancer therapy. (2012) Nat Med. 18(5):636-7.

Products are for research use only. Not for human use.

热销产品